Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

ting activities:

Depreciation and amortization 34,159 27,496

Amortization of premiums on investments, net

of accretion of discounts 4,576 3,204

Stock-based compensation charges 19,651 23,723

Stock option income tax benefits 2,596 191

Excess tax benefit from employee stock options (14,606) (9,187)

Loss on disposal of property and equipment 201 99

Impairment of fixed assets 502 -

Changes in assets and liabilities:

Accounts receivable (16,180) 6,544

Inventories 3,588 (7,798)

Prepaid expenses (6,141) (595)

Other current assets (2,307) 1,683

Other long-term assets (1,131) (2,147)

Accounts payable (1,818) (471)

Accrued salaries and employee benefits 4,273 2,063

Other accrued expenses 679 (27)

Income tax payable (397) 9,970

Deferred revenue 2,855 (7,516)

Deferred income tax (7,621) (6,559)

Deferred rent (118) (112)

Deferred compensation plan liabilities 683 961

Net cash provided by operating activities 109,584 101,020

Investing activities:

Proceeds from sales and maturities of

short-term investments 140,988 132,657

Purchases of short-term investments (298,824)
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email: